Visceral Adipose Tissue (VAT): Drugs That Distort Your DEXA Result

Import from '@/components/mdx'

What Visceral Adipose Tissue Actually Is

VAT is the fat depot that wraps around your liver, pancreas, intestines, and other abdominal organs. It is not the pinchable fat under your skin. It behaves more like an endocrine organ than simple energy storage, secreting inflammatory cytokines, free fatty acids, and adipokines that drive insulin resistance, dyslipidemia, and cardiovascular disease.

DEXA (dual-energy X-ray absorptiometry) can estimate VAT volume or area from an abdominal region of interest scan. DEXA-derived VAT correlates well with MRI-quantified visceral fat and is increasingly standard in metabolic clinics because it adds precision beyond waist circumference alone.

Why VAT Matters More Than Total Body Weight

Two women can have identical BMIs and very different VAT. A woman with a BMI of 26 but high VAT carries more cardiometabolic risk than a woman with a BMI of 30 but mostly subcutaneous fat. The Endocrine Society's 2023 obesity guidelines explicitly recognize adiposity-based chronic disease as a clinical diagnosis that should use body composition, not weight alone.

How VAT Differs From Subcutaneous Fat

Subcutaneous adipose tissue (SAT) is hormonally quieter. VAT drains directly into the portal circulation, dumping free fatty acids and inflammatory signals straight into the liver. This is why high VAT, not high total fat mass, predicts non-alcoholic fatty liver disease, type 2 diabetes, and atherosclerosis so reliably.

Normal VAT Range for Women

A VAT area below 100 cm² on DEXA is the most commonly cited low-risk threshold in women, derived from population studies showing that metabolic risk markers rise sharply above this value. Some researchers and clinics use 80 cm² as a more conservative cut-off for premenopausal women.

A 2011 study in Obesity using DEXA found that a VAT area of 100 cm² corresponded to clinically meaningful elevations in fasting insulin, triglycerides, and blood pressure in women. The American Association of Clinical Endocrinology (AACE) framework for cardiometabolic risk staging uses abdominal obesity as a core criterion, and DEXA-measured VAT is now one of the preferred quantification methods in specialist settings.

Life-Stage Reference Points

| Life stage | Typical VAT pattern | Notes | |---|---|---| | Reproductive years (18-44) | Predominantly subcutaneous | Estrogen promotes gluteofemoral fat storage | | Perimenopause (40-52) | VAT begins rising even before final period | Progesterone decline may start the shift | | Post-menopause | VAT rises ~2-3× premenopausal level | Accelerated in first 2 years after menopause | | PCOS at any age | Elevated VAT for BMI | Hyperandrogenism and insulin resistance both promote visceral deposition |

A longitudinal study published in Menopause showed that women gained an average of 11 cm² of VAT per year during the menopausal transition, independent of changes in total body weight.

How Estrogen and Progesterone Shape VAT

Estrogen is the reason premenopausal women store less visceral fat than age-matched men. Estrogen receptor alpha (ERα) on adipocytes promotes fat storage in the gluteofemoral and subcutaneous compartments. Animal and human data confirm that ERα activation suppresses visceral adipogenesis, which is why surgical menopause (bilateral oophorectomy) causes a faster and larger VAT increase than natural menopause.

Progesterone's role is less clear. Some evidence suggests it mildly promotes visceral deposition, which is why the late luteal phase can produce transient bloating and fluid shifts, though these are not the same as true VAT accumulation.

Androgens, including testosterone and DHEA, actively drive visceral fat deposition in women. This is one reason women with PCOS, who have relatively higher androgen levels, carry more VAT than BMI-matched controls without PCOS.

Drugs That Raise VAT (and Distort Your DEXA Reading)

If you are tracking VAT over time for metabolic monitoring, knowing which medications inflate the number matters as much as knowing the number itself. The following drug classes have the strongest evidence for increasing VAT in women.

Glucocorticoids

Systemic glucocorticoids, such as prednisone, dexamethasone, and methylprednisolone, are the most potent pharmacological drivers of visceral fat accumulation. They activate glucocorticoid receptors on visceral adipocytes more strongly than on subcutaneous ones, promoting differentiation and fat storage centrally.

A meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that chronic glucocorticoid use (>3 months) increased VAT area by a mean of 24 cm² compared to controls. Even inhaled corticosteroids at high doses have shown modest VAT increases in long-term use, though the effect is much smaller than with systemic therapy.

If you are on prednisone 7.5 mg per day or more for longer than 12 weeks, your VAT reading on DEXA likely reflects drug effect as much as baseline metabolic risk. Document the medication and dose on your DEXA requisition.

Atypical Antipsychotics

Olanzapine, clozapine, and quetiapine cause weight gain through multiple mechanisms including H1-receptor blockade (appetite increase) and direct effects on adipose tissue differentiation. The weight gain with these agents is preferentially visceral. A 2013 trial in Schizophrenia Research found that olanzapine increased VAT by 18% over 12 weeks independent of total weight gain.

Aripiprazole and ziprasidone carry lower VAT-gain risk, though they are not neutral.

Insulin at High Doses

High-dose insulin therapy, particularly in type 2 diabetes with insulin resistance, can increase VAT. Insulin promotes lipogenesis and inhibits lipolysis. Because visceral fat has higher blood flow and greater sensitivity to certain anabolic signals, high circulating insulin levels tend to deposit fat centrally over time. The clinical picture is complicated because the underlying diabetes also drives VAT, so separating drug from disease effect is hard without a baseline DEXA.

Medroxyprogesterone Acetate (Depo-Provera)

Depot medroxyprogesterone acetate (DMPA) has glucocorticoid-like receptor activity in addition to progestogenic effects. A prospective study published in Contraception found that DMPA users gained significantly more VAT over 12 months compared to users of copper IUD or combined oral contraceptives. This is clinically relevant for women who are already at risk for insulin resistance, including those with PCOS.

Levonorgestrel-containing IUDs deliver progestin locally with minimal systemic absorption and do not appear to meaningfully affect VAT.

Certain Antiretroviral Agents

Older protease inhibitors (ritonavir, lopinavir) cause visceral fat accumulation as part of HIV-associated lipodystrophy. Newer integrase strand transfer inhibitors are less problematic but not entirely neutral. Women living with HIV on long-term ART who track VAT should note the regimen on every DEXA record.

Thiazolidinediones (TZDs)

Pioglitazone and rosiglitazone are a nuanced case. TZDs reduce hepatic fat and improve insulin sensitivity, and they shift fat from visceral to subcutaneous depots. Total body fat often increases. So a woman on pioglitazone may see her DEXA VAT number fall while her total fat mass rises. This is generally a metabolically favorable shift, but it complicates interpretation if you do not know the drug history.

Drugs That Lower VAT

GLP-1 Receptor Agonists

GLP-1 receptor agonists are the most clinically significant VAT-lowering drug class currently available. Semaglutide, liraglutide, and tirzepatide all reduce VAT substantially.

In the STEP 1 trial of semaglutide 2.4 mg weekly, participants lost an average of 14.9% of body weight, with DEXA subscans showing preferential loss of visceral fat. Women made up 74% of the STEP 1 population, making this one of the most female-representative weight-loss trial datasets available.

Tirzepatide (GIP/GLP-1 dual agonist) showed even larger VAT reductions in the SURMOUNT-1 trial. At 72 weeks, the 15 mg tirzepatide arm showed approximately 40% reduction in visceral fat mass by CT imaging.

Metformin

Metformin modestly reduces VAT, particularly in women with PCOS and insulin resistance. A randomized trial in women with PCOS published in Fertility and Sterility found that metformin 1500 mg per day for 6 months reduced VAT area by approximately 8 cm² compared to placebo. The effect is smaller than GLP-1 agents but meaningful given metformin's safety profile.

Menopausal Hormone Therapy

This is where the data is most directly relevant to perimenopausal and postmenopausal women. Estrogen therapy, particularly transdermal 17-beta estradiol, attenuates the VAT increase that occurs after menopause. The KEEPS trial (Kronos Early Estrogen Prevention Study) found that women randomized to transdermal estradiol had significantly less visceral fat accumulation over 4 years compared to placebo.

Oral estrogen has a less clear VAT effect and may increase triglycerides through first-pass hepatic metabolism. Transdermal delivery avoids this.

The addition of a progestogen matters. Micronized progesterone (Prometrium) appears metabolically neutral compared to medroxyprogesterone acetate, which has glucocorticoid-like activity and may partly blunt the VAT benefit of estrogen.

A Practical Framework: Reading a VAT Number in the Context of Medications

Before interpreting any DEXA-derived VAT result, ask these four questions:

1. Is the patient on a glucocorticoid, atypical antipsychotic, DMPA, or high-dose insulin? If yes, the VAT number may be pharmacologically inflated.
2. Is the patient on a GLP-1 agent, metformin, or transdermal estrogen? If yes, the VAT number may reflect drug-mediated suppression of a higher underlying biological set point.
3. What is the patient's menopausal status? A postmenopausal woman off hormone therapy will have a higher VAT at any given BMI than a premenopausal woman.
4. Has the patient been on the same regimen for at least 3 months? VAT changes slowly; a DEXA taken within weeks of starting or stopping a drug may not reflect steady state.

This four-question check changes clinical interpretation and should be documented in every metabolic consult note.

VAT and Female-Specific Conditions

PCOS

Women with PCOS have higher VAT than BMI-matched controls without the condition. Hyperandrogenism, hyperinsulinemia, and disrupted adipokine secretion all contribute. A 2012 meta-analysis in Human Reproduction found that women with PCOS had significantly higher waist circumference and VAT even after controlling for BMI. Tracking VAT by DEXA in PCOS is more informative than BMI alone because many affected women are normal weight by BMI but carry excess visceral fat.

Treatment that reduces androgen levels (spironolactone, combined oral contraceptives) may modestly reduce VAT, though the evidence here is thinner than for GLP-1 agents.

Endometriosis

Endometriosis is associated with systemic inflammation and disrupted adipokine patterns. Some data suggest lower total fat mass in women with endometriosis, but VAT-specific data are sparse. Evidence remains limited and largely observational, so VAT interpretation in endometriosis requires caution.

Perimenopause and Menopause

As outlined above, the menopausal transition is the most significant biological driver of VAT increase in women's lives. A woman who gains no weight between ages 45 and 55 can still see her VAT rise substantially as fat redistributes from subcutaneous to visceral compartments. Symptom burden (poor sleep from hot flashes, fatigue) compounds the problem by reducing physical activity and increasing cortisol, both of which favor visceral fat storage.

Thyroid Disease

Hypothyroidism, which is far more common in women than men, promotes VAT accumulation through reduced resting energy expenditure and altered lipid metabolism. Subclinical hypothyroidism (TSH 4-10 mIU/L with normal free T4) has been associated with higher VAT independent of BMI in cross-sectional studies. A study in Thyroid found that even mildly elevated TSH was associated with greater visceral fat area on CT imaging in women.

Pregnancy, Lactation, and Contraception Considerations

DEXA during pregnancy is contraindicated. Even though radiation exposure from DEXA is low (approximately 1-4 μSv per scan, far below the 50 mSv threshold associated with fetal harm), no indication justifies elective ionizing radiation during pregnancy. VAT assessment by DEXA should be deferred until after delivery and cessation of breastfeeding.

Postpartum VAT. Pregnancy physiologically increases visceral fat to support fetal growth and lactation energy reserves. Research published in the American Journal of Obstetrics and Gynecology found that women who breastfed for at least 6 months postpartum had lower VAT at 12 months compared to those who formula-fed. This is one of the metabolic benefits of breastfeeding that is rarely communicated clearly.

Contraception and VAT. If you are trying to reduce VAT and are also seeking contraception:

• DMPA (Depo-Provera) has the strongest evidence for raising VAT and should be avoided in women with PCOS, pre-diabetes, or existing elevated VAT.
• Combined oral contraceptives containing levonorgestrel or norgestrel (more androgenic progestins) may have less favorable metabolic profiles than those containing norethindrone or drospirenone.
• A levonorgestrel IUD (Mirena, Liletta) delivers progestin locally; systemic absorption is minimal and VAT effects appear neutral.
• A copper IUD is hormonally inert and has no VAT effect.

GLP-1 agents and contraception. Semaglutide and tirzepatide are contraindicated in pregnancy. The FDA label for semaglutide (Wegovy/Ozempic) states it should be discontinued at least 2 months before a planned pregnancy. Women of reproductive age using GLP-1 agents must use reliable contraception. GLP-1 agents may also alter oral contraceptive absorption by slowing gastric emptying; barrier or intrauterine backup is prudent.

How to Interpret a Changing VAT Number Over Time

A single VAT number is less useful than a trend. Serial DEXA scans, done on the same machine with the same software, spaced at least 6 months apart, give you actionable data. Expect:

• A minimum 3-6 month lag before lifestyle or medication changes show up clearly in VAT.
• GLP-1 agents: meaningful VAT reduction visible by 3-4 months, maximal effect by 12-18 months.
• Glucocorticoid-driven VAT: may begin rising within 4-6 weeks of starting systemic therapy.
• Menopause-related VAT increase: gradual, roughly 2-4 cm² per year during the transition, accelerating in the first 2 years after the final menstrual period.

Scan-to-scan variability on DEXA for VAT is approximately 5-8 cm², so changes smaller than 10 cm² should be interpreted cautiously unless accompanied by other metabolic markers moving in the same direction (fasting insulin, triglycerides, waist circumference).

Who Should Track VAT by DEXA

VAT monitoring is most useful for women who fall into one or more of these categories:

• PCOS with insulin resistance or pre-diabetes
• Perimenopause or post-menopause with any cardiovascular risk factor
• Starting or stopping a GLP-1 agent, glucocorticoid, or atypical antipsychotic
• Normal BMI with metabolic abnormalities (the "metabolically obese normal weight" phenotype)
• Family history of early cardiovascular disease or type 2 diabetes
• Non-alcoholic fatty liver disease or elevated ALT without another explanation

Routine VAT screening by DEXA is not currently recommended by USPSTF or ACOG for all women. The ADA Standards of Care recommend body composition assessment in people with diabetes or pre-diabetes when BMI does not capture cardiometabolic risk.

Evidence Gaps: What We Do Not Know Yet

Women have been historically underrepresented in body composition and metabolic trials. Most VAT reference ranges were derived from populations that skewed male or did not stratify by menopausal status or hormonal contraceptive use. What is directly studied in women:

• GLP-1 effects on VAT: reasonably good female-specific data from STEP 1 (74% women) and SURMOUNT-1.
• Estrogen therapy effects on VAT: moderate-quality data from KEEPS and smaller RCTs.
• Glucocorticoid effects on VAT: mostly extrapolated from mixed-sex trials.

What is extrapolated from mixed-sex or male-dominant data:

• Normal VAT thresholds: the 100 cm² cut-off was not derived from a female-only population.
• Antiretroviral effects on VAT in women: most lipodystrophy data came from male-dominant early HIV cohorts.
• Atypical antipsychotic VAT effects: women may gain more weight on olanzapine than men, but VAT-specific female data are thin.

Clinicians at WomanRx flag this gap routinely. When a woman asks why her VAT number does not match how she feels or what her other labs show, the honest answer is often that the reference range was not built for her.